个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Diagnostic accuracy of CT and PET/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Li Yuepeng[1] * ; Deng Junyue[2] ; Ma Xuelei[3] ; Li Weimin[1,4,5,6] ; Wang Zhoufeng[1,4,5,6] ;
机构： [1]Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China. [2]West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [4]Institute of Respiratory Health, West China Hospital, Sichuan University, Chengdu, China. [5]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China. [6]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, China.
出处：
DOI： 10.1007/s00330-024-11036-4
ISSN：

关键词： Non-small-cell lung carcinoma Radiomics Lymphatic metastasis Meta-analysis

摘要：
This study evaluates the accuracy of radiomics in predicting lymph node metastasis in non-small cell lung cancer, which is crucial for patient management and prognosis.Adhering to PRISMA and AMSTAR guidelines, we systematically reviewed literature from March 2012 to December 2023 using databases including PubMed, Web of Science, and Embase. Radiomics studies utilizing computed tomography (CT) and positron emission tomography (PET)/CT imaging were included. The quality of studies was appraised with QUADAS-2 and RQS tools, and the TRIPOD checklist assessed model transparency. Sensitivity, specificity, and AUC values were synthesized to determine diagnostic performance, with subgroup and sensitivity analyses probing heterogeneity and a Fagan plot evaluating clinical applicability.Our analysis incorporated 42 cohorts from 22 studies. CT-based radiomics demonstrated a sensitivity of 0.84 (95% CI: 0.79-0.88, p < 0.01) and specificity of 0.82 (95% CI: 0.75-0.87, p < 0.01), with an AUC of 0.90 (95% CI: 0.87-0.92), indicating no publication bias (p-value = 0.54 > 0.05). PET/CT radiomics showed a sensitivity of 0.82 (95% CI: 0.76-0.86, p < 0.01) and specificity of 0.86 (95% CI: 0.81-0.90, p < 0.01), with an AUC of 0.90 (95% CI: 0.87-0.93), with a slight publication bias (p-value = 0.03 < 0.05). Despite high clinical utility, subgroup analysis did not clarify heterogeneity sources, suggesting influences from possible factors like lymph node location and small subgroup sizes.Radiomics models show accuracy in predicting lung cancer lymph node metastasis, yet further validation with larger, multi-center studies is necessary.Radiomics models using CT and PET/CT imaging may improve the prediction of lung cancer lymph node metastasis, aiding personalized treatment strategies.International Prospective Register of Systematic Reviews (PROSPERO), CRD42023494701. This study has been registered on the PROSPERO platform with a registration date of 18 December 2023. https://www.crd.york.ac.uk/prospero/ KEY POINTS: The study explores radiomics for lung cancer lymph node metastasis detection, impacting surgery and prognosis. Radiomics improves the accuracy of lymph node metastasis prediction in lung cancer. Radiomics can aid in the prediction of lymph node metastasis in lung cancer and personalized treatment.© 2024. The Author(s), under exclusive licence to European Society of Radiology.

基金：
This work was supported by the National Natural Science Foundation of China (no. 92159302 to W.L.); the Science and Technology Project of Sichuan (2022ZDZX0018 to W.L.); and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD22009 to W.L.).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 核医学
第一作者：
第一作者机构： [1]Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China.
通讯作者：
通讯机构： [1]Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China. [4]Institute of Respiratory Health, West China Hospital, Sichuan University, Chengdu, China. [5]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China. [6]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, China.
推荐引用方式(GB/T 7714)：
Li Yuepeng,Deng Junyue,Ma Xuelei,et al.Diagnostic accuracy of CT and PET/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer[J].European Radiology.2024,doi:10.1007/s00330-024-11036-4.
APA：
Li Yuepeng,Deng Junyue,Ma Xuelei,Li Weimin&Wang Zhoufeng.(2024).Diagnostic accuracy of CT and PET/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer.European Radiology,,
MLA：
Li Yuepeng,et al."Diagnostic accuracy of CT and PET/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer".European Radiology .(2024)

相关文献

[1]EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis [2]阿法替尼治疗晚期非小细胞肺癌临床疗效和安全性的Meta分析 [3]非小细胞肺癌ERCC1表达与铂类药物疗效相关性的荟萃分析 [4]Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome [5]Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma [6]非小细胞肺癌ERCC1表达与铂类药物疗效相关性的荟萃分析 [7]Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance [8]阿法替尼治疗晚期非小细胞肺癌临床疗效和安全性的Meta分析 [9]Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome [10]Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

资源点击量：52804 今日访问量：0 总访问量：4559 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号